Thermo Fisher Scientific

Plainville, MA · Alachua, FL · Cambridge, MA
Find alternatives to Thermo Fisher Scientific for AAV →
AAV Lentiviral Plasmid DNA Adenoviral Plasmid Small Molecule API Oral Solid Dose Sterile Fill-Finish
2 confirmed programs · 2 sponsors · Last scored 2026-11-12
77.7
Signal Score
✓ FDA Inspections (19) ✓ Clinical Trials (2) ✓ SEC Filings (20) ✓ Press (20) ✓ EMA GMP (1) ✓ MHRA GMP (9) ✓ HC GMP (74)

Quick Facts: Thermo Fisher Scientific

Signal Score
77.7/100 (as of 2026-11-12)
Quality Compliance
93.3/100 — Bonus: 3 consecutive NAI inspections
Headquarters
Plainville, MA · Alachua, FL · Cambridge, MA
Modalities
AAV, Lentiviral, Plasmid DNA, Adenoviral, Plasmid, Small Molecule API, Oral Solid Dose, Sterile Fill-Finish
Active Programs
2 confirmed from ClinicalTrials.gov across 2 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Thermo Fisher Scientific

Acquired Brammer Bio ($1.7B, 2019).

Signal Score & Pillar Breakdown

Quality Compliance 93.3
Bonus: 3 consecutive NAI inspections
Clean MHRA record: 9 compliant GMP certificates (no deductions)
Sources: FDA Data Dashboard, EMA EudraGMDP, MHRA GMDP
Bonus: 3 consecutive NAI inspections · Clean MHRA record: 9 compliant GMP certificates (no deductions)
FDA Inspections19 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2026-06-30)
EMA GMP Certificates1 on record
MHRA GMP Certificates9 on record
Most Recent HC OutcomeCompliant · 2025-10-14
HC Attribution74 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Bonus: 3 consecutive NAI inspections
Clean MHRA record: 9 compliant GMP certificates (no deductions)
Operations 60.0
2 active programs across 2 sponsors
Modalities: Small Molecule API, Sterile Fill-Finish, Oral Solid Dose, Adenoviral, AAV, Plasmid DNA, Plasmid, Lentiviral
2 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
2 active programs across 2 sponsors · Modalities: Small Molecule API, Sterile Fill-Finish, Oral Solid Dose, Adenoviral, AAV, Plasmid DNA, Plasmid, Lentiviral · 2 programs in advanced phases (Phase 2/3)
Programs 2
Sponsors2
ModalitiesAAV, Lentiviral, Plasmid DNA, Adenoviral, Plasmid, Small Molecule API, Oral Solid Dose, Sterile Fill-Finish
2 active programs across 2 sponsors
Modalities: Small Molecule API, Sterile Fill-Finish, Oral Solid Dose, Adenoviral, AAV, Plasmid DNA, Plasmid, Lentiviral
2 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
Partnership Signals (from press monitoring)
Company announcements, not verified evidence.
NCT02340936 Clinical Trial to Determinate Dose, Security and Efficacy or... PHASE1/PHASE2 Completed
NCT00982111 First-line Treatment of Patients With Stage IV Nonsquamous... PHASE3 Completed
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Financial Stability 75.0
Publicly traded — financial transparency
Source: company profile (public/private status, parent company)
20 SEC filings with industry mentions on record (shown, not scored)
SEC Filings20 with industry mentions (not scored)
Publicly traded — financial transparency
Capacity 75.0
Multi-site operations (15 manufacturing sites)
Broad modality coverage (8 modalities)
Sites: Plainville, MA, Lexington, MA, Alachua, FL, Greenville, NC, Cincinnati, OH, St. Louis, MO, Allentown, PA, High Point, NC, Horsham, United Kingdom, Bishop's Stortford, United Kingdom, Carrigaline, Ireland, Ferentino, Italy, Monza, Italy, Groningen, Netherlands, Whitby, Canada
Source: company profiles (manufacturing sites, modality breadth)
15 manufacturing sites
StatusAvailable
Multi-site operations (15 manufacturing sites)
Broad modality coverage (8 modalities)
Sites: Plainville, MA, Lexington, MA, Alachua, FL, Greenville, NC, Cincinnati, OH, St. Louis, MO, Allentown, PA, High Point, NC, Horsham, United Kingdom, Bishop's Stortford, United Kingdom, Carrigaline, Ireland, Ferentino, Italy, Monza, Italy, Groningen, Netherlands, Whitby, Canada
Press Signals20 articles (not scored)
Multi-site operations (15 manufacturing sites)
Broad modality coverage (8 modalities)

Thermo Fisher Scientific FDA Inspection History

2026-06
2026-05
2025-09
2025-09
2025-07
2024-11
2024-08
2024-06
2024-03
2024-02
2023-12
2023-06
2023-04
2023-03
2023-03
2023-02
2023-02
2022-08
2021-11
NAI VAI OAI
Date Site Type 483 citations posted Classification
2026-06-30
Patheon Manufacturing Services LLC
Greenville, North Carolina Facility-linked
Vaccines and Allergenic Products Not posted No Action Indicated (NAI)
2026-05-07
Fisher Clinical Services, Inc.
Allentown, Pennsylvania Facility-linked
Drug Quality Assurance Not posted No Action Indicated (NAI)
2025-09-26
Patheon Manufacturing Services LLC
Greenville, North Carolina Facility-linked
Drug Quality Assurance Not posted No Action Indicated (NAI)
2025-09-26
Patheon Pharmaceuticals Inc.
Cincinnati, Ohio Facility-linked
Drug Quality Assurance Yes Voluntary Action Indicated (VAI)
2025-07-17
ThermoFisher Scientific dba Patheon Softgels Inc.
High Point, North Carolina Facility-linked
Drug Quality Assurance Yes Voluntary Action Indicated (VAI)
2024-11-20
Patheon Biologics LLC
Saint Louis, Missouri Facility-linked
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2024-08-21
Patheon Biologics B.V.
Groningen Company-level
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2024-06-13
Patheon Manufacturing Services LLC
Ridgefield, New Jersey Company-level
Vaccines and Allergenic Products Yes Voluntary Action Indicated (VAI)
2024-03-18
Patheon Manufacturing Services LLC
Ridgefield, New Jersey Company-level
Drug Quality Assurance Yes Voluntary Action Indicated (VAI)
2024-02-23
Patheon Manufacturing Services LLC
Greenville, North Carolina Facility-linked
Vaccines and Allergenic Products Yes Voluntary Action Indicated (VAI)
2023-12-08
Patheon Biologics LLC
Saint Louis, Missouri Facility-linked
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2023-06-08
Fisher Clinical Services, Inc.
Allentown, Pennsylvania Facility-linked
Drug Quality Assurance Not posted No Action Indicated (NAI)
2023-04-21
Patheon Pharmaceuticals Inc.
Cincinnati, Ohio Facility-linked
Drug Quality Assurance Not posted No Action Indicated (NAI)
2023-03-28
Patheon Biologics B.V.
Groningen Company-level
Drug Quality Assurance Not posted No Action Indicated (NAI)
2023-03-02
Patheon Biologics LLC
Saint Louis, Missouri Facility-linked
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2023-02-24
Patheon Inc.
Mississauga Company-level
Drug Quality Assurance Yes Voluntary Action Indicated (VAI)
2023-02-17
Patheon Inc.
Whitby Company-level
Drug Quality Assurance Yes Voluntary Action Indicated (VAI)
2022-08-04
Patheon Manufacturing Services LLC
Greenville, North Carolina Facility-linked
Vaccines and Allergenic Products Yes Voluntary Action Indicated (VAI)
2021-11-09
Patheon Biologics B.V.
Groningen Company-level
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
Source: FDA Data Dashboard · Retrieved Nov 21, 2026

Thermo Fisher Scientific FDA 483 Findings 18 observations · 2022-08-04 → 2025-09-26 ?

By subsystem

  • Documentation & Records 7 (38.9%)
  • CAPA 5 (27.8%)
  • Equipment & Facilities 3 (16.7%)
  • Laboratory Controls 2 (11.1%)
  • Environmental Monitoring 1 (5.6%)

By severity

  • 4 — Serious: 1
  • 3 — Moderate: 7
  • 2 — Minor: 10
  • Repeat observations: 1

Most severe findings

  • Serious (4) Environmental Monitoring 2024-06-13 21 CFR 211.42(c)(10)(iv)
    Environmental Monitoring System

    "Aseptic processing areas are deficient regarding the system for monitoring environmental conditions."

  • Moderate (3) CAPA 2025-09-26 21 CFR 211.192
    Investigations of discrepancies, failures

    "There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed."

  • Moderate (3) CAPA 2024-06-13 21 CFR 211.192
    Investigations of discrepancies, failures

    "There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed."

Thermo Fisher Scientific EMA GMP Compliance 1 certificates

2025-11
Compliant Non-Compliant
Certificate Site Country Inspection Date Status
CRN00GTCX/ASR12633 Thermo Fisher Scientific Cork Limited Ireland 2025-11-07 COMPLIANT
Source: EMA EudraGMDP · Retrieved Nov 21, 2026

Thermo Fisher Scientific MHRA GMP Compliance 9 certificates

2024-10
2024-10
2024-07
2024-07
2024-07
2021-03
2019-08
2019-01
2017-01
Compliant Non-Compliant
Certificate Site City / Postcode Inspection Date Status
UK MIA 18693 Insp GMP/GDP/IMP 18693/11204-0018[H] FISHER CLINICAL SERVICES UK LIMITED HORSHAM RH12 4QD 2024-10-08 COMPLIANT
UK MIA(IMP) 18693 Insp GMP/GDP/IMP 18693/11204-0019[I] FISHER CLINICAL SERVICES UK LIMITED HORSHAM RH12 4QD 2024-10-08 COMPLIANT
UK MIA 17857 Insp GMP/IMP 17857/10036-0034[H] PATHEON UK LIMITED SWINDON SN3 5BZ 2024-07-29 COMPLIANT
UK MIA(IMP) 17857 Insp GMP/IMP 17857/10036-0034[I] PATHEON UK LIMITED SWINDON SN3 5BZ 2024-07-29 COMPLIANT
UK MIA(IMP) 32390 Insp GMP/IMP 32390/411870-0007[I] THERMO ELECTRON LIMITED BISHOP'S STORTFORD CM23 5RG 2024-07-16 COMPLIANT
UK MIA(IMP) 17857 Insp GMP/IMP 17857/14285-0011[I] PATHEON UK LIMITED ABINGDON OX14 4SD 2021-03-24 COMPLIANT
UK MIA(IMP) 32390 Insp IMP 32390/18853104-0001[I] THERMO ELECTRON LIMITED STEVENAGE SG1 2FX 2019-08-29 COMPLIANT
UK MIA(IMP) 18693 Insp GMP/GDP/IMP 18693/11485563-0003[I] FISHER CLINICAL SERVICES LIMITED CRAWLEY RH10 9NL 2019-01-21 COMPLIANT
UK GMP 20788 Insp GMP 20788/13917-0005[H] PATHEON PHARMACEUTICALS INCORPORATED 45237 2017-01-17 COMPLIANT
Source: MHRA GMDP Database · Retrieved Nov 21, 2026

Japan-accredited overseas site (PMDA)

sterile, biologics, general (non-sterile), packaging/storage only, CGT packaging/storage only · 9 sites

  • Carrigaline, Ireland · Thermo Fisher Scientific Cork Limited — general (non-sterile) · valid to Oct 28, 2029
  • Groningen, Netherlands · Patheon Biologics B.V. — biologics · valid to Jun 6, 2027
  • Horsham, United Kingdom · Fisher Clinical Services UK Limited — packaging/storage only · valid to Jan 8, 2030
  • Allentown, United States · Fisher Clinical Services, Inc. — biologics, CGT packaging/storage only · valid to Jun 7, 2031
  • Cincinnati, United States · Patheon Pharmaceuticals Inc. — general (non-sterile) · valid to Feb 14, 2030
  • Greenville, United States · Patheon Manufacturing Services LLC — sterile, biologics, general (non-sterile) · valid to Dec 31, 2026 renewal filed
  • Ridgefield, United States · Patheon Manufacturing Services LLC (2 sites) — sterile, packaging/storage only · valid to Aug 31, 2030
  • Saint Louis, United States · Patheon Biologics LLC — biologics · valid to Jul 20, 2031
Previously accredited (cancelled) · 2
  • Groningen, Netherlands · Patheon Biologics B.V. — biologics · cancelled Sep 30, 2023
  • Swindon, United Kingdom · Patheon UK Limited — sterile, general (non-sterile) · cancelled Aug 21, 2017

No longer on PMDA's current list. Shown for history only; not used in search tags.

PMDA accreditation of a foreign manufacturing site is recognition within Japan's regulatory system, not an inspection outcome. PMDA's list covers only manufacturing sites outside Japan, so a company's plants in Japan are not on it. Source: PMDA, list of accredited/registered foreign manufacturers (as of Oct 16, 2026), Public Data License 1.0 (terms)

Hiring Activity 299 open roles Beta

From public job postings on the parent company's careers board, as of Nov 20, 2026. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
299
open roles
224
in manufacturing, quality, PD/MSAT, engineering or regulatory (75%)
Trend from Nov 30, 2026
Tracking started Oct 26, 2026. 30-day change shows after 30 days, 90-day after Jan 29, 2027.
Since Nov 19, 2026: 53 new postings, 2569 taken down.
What this may mean
  • 6 of the 13 openings at Brisbane, Queensland, Australia are in quality (QA/QC). That fits added testing or batch-release work, but it can also be normal turnover.
  • 6 job titles mention mRNA (Monza, Monza e Brianza, Italy). That points to mRNA work there as of Nov 20, 2026, not to its size or stage.
By function
Manufacturing & operations 54
Quality (QA / QC) 64
Process development & MSAT 64
Regulatory 1
Engineering & facilities 41
Commercial, BD & client projects 23
Other (finance, HR, IT, other) 52
By site
Greenville, North Carolina, United States of America profile site
6 mfg/ops · 25 QA/QC · 20 PD/MSAT · 11 eng. · 12 other
74
Monza, Monza e Brianza, Italy profile site
8 mfg/ops · 5 QA/QC · 1 PD/MSAT · 7 eng. · 12 other
33
Cincinnati, Ohio, United States of America profile site
4 mfg/ops · 3 QA/QC · 13 PD/MSAT · 4 eng. · 6 other
30
Covingham, Swindon, Wiltshire, United Kingdom
3 mfg/ops · 7 QA/QC · 3 PD/MSAT · 3 eng. · 8 other
24
Allentown, Pennsylvania, United States of America profile site
9 mfg/ops · 2 QA/QC · 3 eng. · 7 other
21
Florence, South Carolina, United States of America
6 mfg/ops · 2 QA/QC · 8 PD/MSAT · 1 eng. · 3 other
20
Plainville, Massachusetts, United States of America profile site
2 mfg/ops · 3 QA/QC · 10 PD/MSAT · 5 other
20
+ 16 more locations
Modality words in job titles
Biologics (cell culture, USP/DSP)8mRNA6
Notable roles
Finance Director Global Central Laboratory CRG Senior operations / quality role · Wilmington, North Carolina, United...
Head of Quality Control Senior operations / quality role · Brisbane, Queensland, Australia
Head of Supply Chain Onsite Florence SC Senior operations / quality role · Florence, South Carolina, United...
Quality Director Senior operations / quality role · Bourgoin Jallieu Cedex, France
Latest postings
Stationary Engineer (nights/days) Engineering & facilities · Greenville, North Carolina, United... · posted Nov 20, 2026
Sr Formulation Technician (12hr days, 2-2-3 rotation) Process development & MSAT · Greenville, North Carolina, United... · posted Nov 20, 2026
Senior Manager, Business Management Other (finance, HR, IT, other) · Covingham, Swindon, Wiltshire, United Kingdom · posted Nov 20, 2026
Program Manager III Commercial, BD & client projects · Plainville, Massachusetts, United... · posted Nov 20, 2026
Process Engineer II, Manufacturing Engineering Process development & MSAT · Plainville, Massachusetts, United... · posted Nov 20, 2026
Inventory Coordinator I - First Shift Manufacturing & operations · Allentown, Pennsylvania, United... · posted Nov 20, 2026
Engineer III - Requalification Quality (QA / QC) · Greenville, North Carolina, United... · posted Nov 20, 2026
Deskside Support Engineer Engineering & facilities · Covingham, Swindon, Wiltshire, United Kingdom · posted Nov 20, 2026
Supervisor, Formulation Manufacturing Process development & MSAT · Greenville, North Carolina, United... · posted Nov 19, 2026
Mass Spec FTIR Regional Sales - Central Commercial, BD & client projects · Austin, Texas, United States of... · posted Nov 19, 2026
Lead formulation technician Process development & MSAT · Covingham, Swindon, Wiltshire, United Kingdom · posted Nov 19, 2026
Formulation Technician II (12hr days; 2-2-3) Process development & MSAT · Greenville, North Carolina, United... · posted Nov 19, 2026
Coverage: read from the parent company's careers board and kept only postings at this business's sites (Pharma Services (Patheon/PSG) sites; the Phenom sitemap has no location, so it needs JSON-LD locations (backfilled up to 300 pages a day)). Roles outside those sites are left out, and some of this unit's roles may be missed. Function groups come mainly from job titles (about 84% match a hand check), and modality words from titles only, so both are approximate.
Source: jobs.thermofisher.com · Checked Nov 20, 2026 · Tracking since Oct 26, 2026

Financial Intelligence

8-K 2026-10-21 0 keyword mentions
"Item 2.02 Results of Operations and Financial Condition: On October 21, 2026, the Registrant announced its financial results for the fiscal quarter ended September 26, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Form 8-K and incorporated herein by reference."
10-Q 2026-07-31 2 keyword mentions
"Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty service agreements, which typically have durations of three to five years ."
8-K 2026-07-23 0 keyword mentions
"Item 2.02 Results of Operations and Financial Condition: On July 23, 2026, the Registrant announced its financial results for the fiscal quarter ended June 27, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Form 8-K and incorporated herein by reference."
8-K 2026-05-26 0 keyword mentions
10-Q 2026-05-01 2 keyword mentions
"Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty service agreements, which typically have durations of three to five years ."
8-K 2026-04-23 0 keyword mentions
8-K 2026-03-24 0 keyword mentions
10-K 2026-02-26 2 keyword mentions
"Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty service agreements, which typically have durations of three to five years ."
8-K 2026-02-12 0 keyword mentions
8-K 2026-01-29 0 keyword mentions
8-K 2026-01-12 0 keyword mentions
8-K 2025-12-01 0 keyword mentions
10-Q 2025-10-31 2 keyword mentions
"Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty service agreements, which typically have durations of three to five years ."
8-K 2025-10-29 0 keyword mentions
10-Q 2025-08-01 1 keyword mentions
"Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty service agreements, which typically have durations of three to five years ."
10-Q 2025-05-02 1 keyword mentions
"Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty service agreements, which typically have durations of three to five years ."
10-K 2025-02-20 1 keyword mentions
"Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty service agreements, which typically have durations of three to five years ."
10-Q 2024-11-01 1 keyword mentions
"Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty service agreements, which typically have durations of three to five years ."
10-Q 2024-08-02 1 keyword mentions
"Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty service agreements, which typically have durations of three to five years ."
10-Q 2024-05-03 1 keyword mentions
"Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty service agreements, which typically have durations of three to five years ."
Source: SEC EDGAR · Retrieved Nov 21, 2026

Company Signals 20 articles

Company announcements, not verified evidence. They do not change any score.
general 2026-05-05
Thermo Fisher Unveils Integrated Platform to Advance Scalable Cell Therapy Manufacturing - Digital Health News
Thermo Fisher Unveils Integrated Platform to Advance Scalable Cell Therapy Manufacturing  Digital Health News
general 2026-05-04
Thermo Fisher Scientific Unveils an Integrated Platform to Advance Scalable Cell Therapy Manufacturing - FinancialContent
Thermo Fisher Scientific Unveils an Integrated Platform to Advance Scalable Cell Therapy Manufacturing  FinancialContent
general 2026-05-04
Thermo Fisher Scientific Introduces Gibco CTS DynaXS Single Use Bioreactor - Contract Pharma
Thermo Fisher Scientific Introduces Gibco CTS DynaXS Single Use Bioreactor  Contract Pharma
general 2026-05-04
Thermo Fisher Scientific Unveils an Integrated Platform to Advance Scalable Cell Therapy Manufacturing - New Castle News
Thermo Fisher Scientific Unveils an Integrated Platform to Advance Scalable Cell Therapy Manufacturing  New Castle News
general 2026-05-04
Thermo Fisher Scientific Unveils an Integrated Platform to Advance Scalable Cell Therapy Manufacturing - The Joplin Globe
Thermo Fisher Scientific Unveils an Integrated Platform to Advance Scalable Cell Therapy Manufacturing  The Joplin Globe
regulatory 2026-05-04
Thermo Fisher introduces integrated platform to advance scalable cell therapy manufacturing - BioSpectrum India
Thermo Fisher introduces integrated platform to advance scalable cell therapy manufacturing  BioSpectrum India
general 2026-04-29
Thermo Fisher Scientific launches applied Biosystems PowerFlex Thermal Cycler - Med-Tech Insights
Thermo Fisher Scientific launches applied Biosystems PowerFlex Thermal Cycler  Med-Tech Insights
partnership 2026-04-29
Thermo Fisher Scientific, SHL Medical Collaborate on Integrated Drug-Device Solutions - Medical Product Outsourcing
Thermo Fisher Scientific, SHL Medical Collaborate on Integrated Drug-Device Solutions  Medical Product Outsourcing
general 2026-04-28
Thermo Fisher Scientific Opens U.S. Flagship Bioprocess Design Center to Accelerate the Delivery of - PharmiWeb.com
Thermo Fisher Scientific Opens U.S. Flagship Bioprocess Design Center to Accelerate the Delivery of  PharmiWeb.com
facility_expansion 2026-04-28
Thermo Fisher Scientific opens bioprocess design center with 4,000 sq. ft. of lab and training space - R&D World
Thermo Fisher Scientific opens bioprocess design center with 4,000 sq. ft. of lab and training space  R&D World
general 2026-04-28
Thermo Fisher opens Plainville design center amid $2B push for U.S. manufacturing - The Business Journals
Thermo Fisher opens Plainville design center amid $2B push for U.S. manufacturing  The Business Journals
facility_expansion 2026-04-28
Thermo Fisher opens new facility for vaccine, gene therapy development - The Boston Globe
Thermo Fisher opens new facility for vaccine, gene therapy development  The Boston Globe
general 2026-04-28
Thermo Fisher Scientific Expands Plainville Facility With Flagship Bioprocess Design Center To Advance Biologics Development - BioPharma APAC
Thermo Fisher Scientific Expands Plainville Facility With Flagship Bioprocess Design Center To Advance Biologics Development  BioPharma APAC
general 2026-04-27
Thermo Fisher Scientific sells microbiology business for $1B to European private equity firm - Fierce Biotech
Thermo Fisher Scientific sells microbiology business for $1B to European private equity firm  Fierce Biotech
regulatory 2026-04-23
Thermo Fisher CEO says onshoring push will bring a ‘tailwind’ for the Waltham company - The Business Journals
Thermo Fisher CEO says onshoring push will bring a ‘tailwind’ for the Waltham company  The Business Journals
general 2026-04-20
Healthcare Filtration Markets 2025-2035 with Focus on Biologics Manufacturing Featuring Alfa Laval, Asahi Kasei, Cobetter, Corning, Merck, Pall, Parker Hannifin, Sartorius, Thermo Fisher Scientific - Yahoo Finance
Healthcare Filtration Markets 2025-2035 with Focus on Biologics Manufacturing Featuring Alfa Laval, Asahi Kasei, Cobetter, Corning, Merck, Pall, Parker Hannifin, Sartorius, Thermo Fisher Scientific  Yahoo Finance
general 2026-04-11
Thermo Fisher Launches Automated Cell Therapy System - Technology Networks
Thermo Fisher Launches Automated Cell Therapy System  Technology Networks
general 2026-04-11
Thermo Fisher Launches Automated Cell Therapy System - Technology Networks
Thermo Fisher Launches Automated Cell Therapy System  Technology Networks
general 2026-04-09
How Investors May Respond To Thermo Fisher Scientific (TMO) Expanding Its Cell Therapy And Biologics Platforms - Sahm
How Investors May Respond To Thermo Fisher Scientific (TMO) Expanding Its Cell Therapy And Biologics Platforms  Sahm
general 2026-04-08
Thermo Fisher Scientific introduces the Gibco CTS Compleo Fill and Finish System - SelectScience
Thermo Fisher Scientific introduces the Gibco CTS Compleo Fill and Finish System  Select Science

Frequently Asked Questions About Thermo Fisher Scientific

How many FDA inspections does Thermo Fisher Scientific have on record?
CDMO Signal tracks 19 FDA inspections for Thermo Fisher Scientific, sourced from the FDA inspection database. See the full inspection history above.
Has Thermo Fisher Scientific received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Thermo Fisher Scientific.
Does Thermo Fisher Scientific hold EMA or MHRA GMP certificates?
CDMO Signal tracks 1 EMA and 9 MHRA GMP certificates for Thermo Fisher Scientific.
How many clinical programs is Thermo Fisher Scientific linked to?
Thermo Fisher Scientific is associated with 2 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Thermo Fisher Scientific's CDMO Signal Score?
Thermo Fisher Scientific has a Signal Score of 78/100, based on quality, operations, financial stability, and capacity data.
Evaluating Thermo Fisher Scientific for a manufacturing program?
Use the free AI matchmaker to compare Thermo Fisher Scientific against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
AAV CDMOs → Lentiviral CDMOs → Plasmid DNA CDMOs → Adenoviral CDMOs → Plasmid CDMOs →

Similar CDMOs

Rose BioSolutions
Rockville, MD · Memphis, TN · Keele, United Kingdom
Signal Score: 64.0
AAV, Lentiviral, Adenoviral, Plasmid, Cell Therapy, CAR-T
Lonza
Basel, Switzerland
Signal Score: 72.8
AAV, Lentiviral, Cell Therapy, mRNA, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation, Small Molecule API, High-Potency APIs, Oral Solid Dose
Pfizer CentreOne
Kalamazoo, MI · McPherson, KS
Signal Score: 90.1
Biologics, mRNA, Small Molecule API, Oral Solid Dose, High-Potency APIs, Sterile Fill-Finish
Pharmaron
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
Signal Score: 86.9
AAV, Lentiviral, Plasmid, mAb, Antibody, Recombinant Protein, Biosimilars
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC

Compare Thermo Fisher Scientific with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on Thermo Fisher Scientific
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.